PIB Tracker
DailyWeeklyMonthlyYearlyBacktestGet early access
🤝 Schemes & WelfareMAINS · GS2.13

Janaushadhi Saptah opens nationwide health camps

A week of generic-medicine outreach begins, building to the 8th Janaushadhi Diwas on 7 March.

What happened

Background & context

Janaushadhi Saptah is the annual mobilisation campaign of the Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) — literally the "Prime Minister's Indian People's Medicine Scheme". The campaign exists to widen public uptake of the Jan Aushadhi Kendras, the dedicated retail outlets through which the scheme sells unbranded, generic versions of medicines at prices far below their branded counterparts. A "week" (Saptah) of camps and awareness activity each year culminates in "Diwas" (day) on 7 March; the 2026 edition is the eighth such observance, placing the first Janaushadhi Diwas at 7 March 2019.

The scheme itself has a longer lineage than the campaign. It was first introduced in 2008 as the Jan Aushadhi Scheme by the Department of Pharmaceuticals, but the early roll-out stalled and the outlet network remained small. It was relaunched and renamed in 2015 as the Pradhan Mantri Bhartiya Janaushadhi Pariyojana, given a fresh implementing structure and an aggressive store-opening target. The current implementing agency, PMBI, is a society under the Department of Pharmaceuticals that procures the generics, manages the supply chain, and franchises the Kendras to entrepreneurs, NGOs, pharmacists and self-help groups who run them.

The administering chain is worth fixing precisely, because it is a common point of confusion. The nodal ministry is the Ministry of Chemicals & Fertilisers — not the Ministry of Health and Family Welfare, which an aspirant might assume given that the scheme is about medicines. Within that ministry, the Department of Pharmaceuticals owns the scheme, and PMBI (also written as the Pharmaceuticals & Medical Devices Bureau) is the operational arm. Pharmaceuticals as a sector sits with Chemicals & Fertilisers in the Government of India's allocation of business, which is why medicine-pricing and generic-access schemes are run from there rather than from the health ministry.

The programme's central proposition is the price gap between generic and branded medicines. A generic drug contains the same active pharmaceutical ingredient, in the same strength and dosage form, as a branded product whose patent has expired; it is required to meet the same quality and bioequivalence standards but carries none of the brand premium or marketing cost. Under PMBJP the saving passed to the consumer is large: Janaushadhi medicines are sold at 50–90% below the prevailing market price of equivalent branded drugs, which is the single number that makes the scheme matter for out-of-pocket health spending.

The Saptah-to-Diwas rhythm is itself a deliberate design. Through the week (1–5 March) the camps bring screening and free medicine to citizens at the doorstep of the Kendras; the campaign then peaks on 7 March, Janaushadhi Diwas, when the programme reports its annual progress — the count of operating outlets, the cumulative consumer savings, and the new products added to the Jan Aushadhi product basket. That product basket is wide: the Kendras stock not only medicines across major therapeutic categories but also surgicals, nutraceuticals and consumer products, including low-cost sanitary napkins sold under the Jan Aushadhi banner. This breadth is part of why the network is positioned as a general affordable-healthcare retail channel rather than a narrow pharmacy.

Placed against its closest institutional peer, the contrast sharpens. The nearest comparison on the affordable-medicine map is the price-control route run through the National Pharmaceutical Pricing Authority (NPPA), which fixes ceiling prices for scheduled essential medicines under the Drug (Prices Control) Order. NPPA caps what every seller may charge for a controlled drug; PMBJP instead opens a parallel retail channel that sells unbranded generics cheaply regardless of branded pricing. One is a regulator setting a ceiling, the other is a state-backed retailer offering a cheaper alternative — complementary instruments aimed at the same out-of-pocket problem from opposite ends.

For Prelims

What it is NOT: Janaushadhi Saptah is not a new scheme — it is the annual awareness week of an existing programme, PMBJP. PMBJP is not run by the Health Ministry; it sits under the Department of Pharmaceuticals (Chemicals & Fertilisers). A Jan Aushadhi Kendra is not a free-medicine outlet — medicines are sold, only at sharply discounted generic prices; the free dispensing happens only during the camp drives. The medicines are generics (off-patent, unbranded), not branded or counterfeit, and are required to meet standard quality and bioequivalence norms. And Janaushadhi is distinct from Ayushman Bharat / PM-JAY (a health-insurance and hospital-care scheme under the Health Ministry) and from the Affordable Medicines and Reliable Implants for Treatment (AMRIT) pharmacies run for cancer and cardiac drugs — all three lower medicine costs but through different channels and different ministries.

The full affordable-medicine set an aspirant should be able to place against one another: PMBJP / Jan Aushadhi Kendras (generic retail, Dept of Pharmaceuticals); AMRIT pharmacies (discounted cancer/cardiac drugs, Health Ministry); the National Pharmaceutical Pricing Authority (NPPA, which caps prices of essential medicines via the Drug Price Control Order); and the National List of Essential Medicines (NLEM), which defines which drugs are price-controlled. Janaushadhi works on the supply-and-retail side (selling cheaper generics), whereas NPPA works on the regulatory side (capping ceiling prices) — a clean contrast UPSC likes to test.

Why it matters

Out-of-pocket expenditure remains one of the largest components of health spending in India, and medicines are among the biggest single items within it. A scheme that delivers the same active ingredient at half to a tenth of the branded price directly reduces the medicine bill for chronic-disease patients — those managing diabetes, hypertension, thyroid disorders and cardiac conditions who buy the same drugs month after month. By targeting day-one camps at exactly these screenings (BP, blood sugar, thyroid), the Saptah links diagnosis to affordable continuing treatment in a single touchpoint.

The programme also addresses a behavioural problem the scheme itself implicitly admits: many patients and even prescribers default to branded drugs out of habit or distrust of generics, despite identical composition. The awareness week, the app, and the free camps are all instruments to close that trust gap and convert footfall into repeat Kendra customers. Scaling the network from 18,000+ to 25,000 outlets is meant to make a Kendra reachable for a far larger share of the population, particularly in smaller towns and rural blocks where branded-drug mark-ups bite hardest. The model is also a livelihood vehicle — Kendras are run as franchises by individual entrepreneurs and self-help groups, so expansion doubles as small-enterprise generation.

For Mains

Exemplification
PMBJP and the Jan Aushadhi Kendra network are a ready example of a government intervention that lowers out-of-pocket health expenditure on the supply side — usable in any answer on access to affordable healthcare or reducing the cost burden of chronic disease.
Substantiation
The hard numbers travel well into a data-backed answer: generics at 50–90% below market price, 18,000+ Kendras operating, and a 25,000-outlet target by March 2027 — concrete evidence of the scale of the affordable-medicine push.
Problematisation
The very need for an annual awareness week, free camps and a locator app signals the gap the scheme is fighting — low public trust in generics and weak last-mile uptake despite identical drug composition — a clean way to frame the demand-side challenge in health-policy answers.
Position
The scheme states the government's stance that affordable generic access is a public good worth a dedicated retail network and a national campaign, distinct from insurance-led models — useful to contrast supply-side (Janaushadhi) and demand-side (PM-JAY) approaches to health affordability.
Way-forward
Network expansion to 25,000 outlets, deeper rural penetration, and digital price-comparison tools point to the direction of travel for widening generic-medicine access — a deployable "way forward" in answers on healthcare delivery.
Deploys into: GS2.13 (health and human-resource development) and GS2.10 (government policies and interventions for vulnerable sections) — affordable healthcare, reducing out-of-pocket spend, and supply-side versus insurance-led health interventions.

Source

Ministry of Chemicals & Fertilisers · Department of Pharmaceuticals · 2026-03-01 · PRID 2234273 · PIB source ↗
Related: PMBJP / Jan Aushadhi hub · Schemes & Welfare · This week's cards